Back to article: Forty-five-year evolution of probiotic therapy

TABLE 1. Probiotic strains and the condition they target.

51. Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, and Takahashi S (2007). Lactobacillus reuteri tablets suppress Helicobacter pylori infection —A double-blind randomised placebo-controlled cross-over clinical study. J Japanese Assoc Infect Dis 81(4): 16–20. doi: 10.11150/kansenshogakuzasshi1970.81.387

52. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Bucci N, Canio A De, Indrio F, Cavallo L, Ierardi E, and Miniello VL (2008). Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy?: A pilot study. Helicobacter 13(2): 127–134. doi: 10.1111/j.1523-5378.2008.00593.x

53. Onini FC, Rtolozzi FBA, Ducci FCAN, Elli MC, Ojetti V, Marota GCAM, Anti M, and Rini GGAS (2001). The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Alimenta 15(2): 163–169. doi: 10.1046/j.1365-2036.2001.00923.x

54. Derwa Y, Gracie DJ, Hamlin PJ, and Ford AC (2017). Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 46(4): 389–400. doi: 10.1111/apt.14203

55. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, and Isolauri E (2001). Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357(9262): 1076–1079. doi: 10.1016/S0140-6736(00)04259-8

84. Petricevic L, and Witt A (2008). The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. Gen Gynaecol 1369–1374. doi: 10.1111/j.1471-0528.2008.01882.x

85. Larsson P-G, Brandsborg E, Forsum U, Pendharkar S, Andersen KK, Nasic S, Hammarström L, and Marcotte H (2011). Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis 11(1): 223. doi: 10.1186/1471-2334-11-223

101. Wang L, Guo M-J, Gao Q, Yang J-F, Yang L, Pang X-L, and Jiang X-J (2018). The effects of probiotics on total cholesterol. Medicine 97(5): e9679. doi: 10.1097/MD.0000000000009679

122. Whorwell PJ, Altringer L, Morel J, Ph D, Bond Y, Charbonneau D, Ph D, Mahony LO, Ph D, Kiely B, Ph D, Shanahan F, and Quigley EMM (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101: 1581–1590. doi: 10.1111/j.1572-0241.2006.00734.x

123. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier C-H, and Matuchansky C (2007). Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26(3): 475–486. doi: 10.1111/j.1365-2036.2007.03362.x

124. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Feuillerat NG, Schlumberger A, Jakob S, and Whorwell PJ (2008). Clinical trial?: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29: 104–114. doi: 10.1111/j.1365-2036.2008.03853.x

125. Yang Y, He M, Hu G, Wei J, Pages P, Yang X, and Bourdu-Naturel S (2008). Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 14(40): 6237–6243. doi: 10.3748/wjg.14.6237

126. Trial P, Ojetti V, Ianiro G, Tortora A, Angelo GD, Antonella T, Rienzo D, Bibbò S, Migneco A, and Gasbarrini A (2014). The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation?: a randomized, double-blind, placebo-controlled trial. J Gastrointest Liver Dis 23(4): 387–391. doi: 10.15403/jgld.2014.1121.234.elr

127. Sampalis J, Psaradellis E, and Rampakakis E (2010). Efficacy of BIO K + CL1285 ® in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 6(1): 56–64. doi: 10.5114/aoms.2010.13508

128. Beausoleil M, Fortier N, Guenette S, L'Ecuyer A, Savoie M, Franco M, Lachaine J, and Weis K (2007). Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 21(11): 732–736. doi: 10.1155/2007/720205

129. Cimperman L, Bayless G, Best K, Diligente A, Mordarski B, Oster M, Smith M, Vatakis F, Wiese D, Steiber A, and Katz J (2011). Study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 45(9): 785–789.

130. Kale-pradhan PB, Pharm D, Jassal HK, Wilhelm SM, and Pharm D (2010). Role of Lactobacillus in the prevention of antibiotic-associated diarrhea?: a meta-analysis. Pharmacotherapy 30(2): 119–126. doi: 10.1592/phco.30.2.119

131. Szajewska H, and Kołodziej M (2015). Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 42(7): 793–801. doi: 10.1111/apt.13344

132. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, and Bruce AW. (2003). Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol. Med. Microbiol 35: 131-134. doi: 10.1016/s0928-8244(02)00465-0

133. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, and Reid G (2006). Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect 8(12–13): 2772–2776. doi: 10.1016/j.micinf.2006.08.008

134. Marcone V, Rocca G, Lichtner M, and Calzolari E (2010). Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Gynecol Obstet 110(3): 223–226. doi: 10.1016/j.ijgo.2010.04.025

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.